Patent classifications
A61K31/131
THIOL-CONTAINING COMPOUNDS FOR USE IN TREATING CORONAVIRUS
Provided herein, inter alia, are methods and compositions including thiol-containing compounds for treating coronavirus infection.
ELAFIBRANOR FOR THE TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS
The present invention relates to elafibranor or its active metabolite for use in a method for treating primary sclerosing cholangitis.
ANALOGS OF ADENOSINE MONOPHOSPHATE (AMP) AS INHIBITORS OF UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME ATG7
Disclosed are analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activing enzyme ATG7. The AMP analogs may be formulated as pharmaceutical compositions for treating diseases or disorders that depend on ATG7 activity and/or autophagy such as cell proliferative diseases and disorders.
ANALOGS OF ADENOSINE MONOPHOSPHATE (AMP) AS INHIBITORS OF UBIQUITIN-LIKE MODIFIER-ACTIVATING ENZYME ATG7
Disclosed are analogs of adenosine monophosphate (AMP) as inhibitors of ubiquitin-like modifier-activing enzyme ATG7. The AMP analogs may be formulated as pharmaceutical compositions for treating diseases or disorders that depend on ATG7 activity and/or autophagy such as cell proliferative diseases and disorders.
Solid Forms of Mirabegron
Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.
Solid Forms of Mirabegron
Solid forms of Mirabegron, including forms APO-I, APO-II, and various salt forms, and processes for the preparation thereof, are provided.
VOLATILE ORGANIC COMPOUNDS FOR INHIBITING FUNGAL GROWTH
Compositions, devices, and methods are disclosed for treating or preventing fungal infection in an animal are provided. The methods involve exposing the animal to one or more volatile organic compounds (VOCs) in a quantity sufficient to inhibit or reduce fungal growth in the animal. Also disclosed is an automated aerosolization unit (AAU) for delivering compositions, such as the disclosed VOCs, to areas, such as habitats, to treat or prevent fungal infections in animals.
VOLATILE ORGANIC COMPOUNDS FOR INHIBITING FUNGAL GROWTH
Compositions, devices, and methods are disclosed for treating or preventing fungal infection in an animal are provided. The methods involve exposing the animal to one or more volatile organic compounds (VOCs) in a quantity sufficient to inhibit or reduce fungal growth in the animal. Also disclosed is an automated aerosolization unit (AAU) for delivering compositions, such as the disclosed VOCs, to areas, such as habitats, to treat or prevent fungal infections in animals.
Composition for stimulating muscle growth, repair, and maintenance
The present invention relates to a composition for stimulating muscle growth, repair and maintenance and the method of using the same. The present invention generally relates to compositions and methods for supporting muscle anabolism. The compositions described herein are pharmaceutical or nutritional compositions suitable for preserving muscle mass, strength, and/or function in a subject in need thereof. The compositions are based on a specially formulated mixture of essential amino acids (EAAs) and protein with additional components. Use of the compositions herein may prevent muscle atrophy associated with periods of rest, such as those following surgery, injury, inactivity and during recovery from disease.
Composition for stimulating muscle growth, repair, and maintenance
The present invention relates to a composition for stimulating muscle growth, repair and maintenance and the method of using the same. The present invention generally relates to compositions and methods for supporting muscle anabolism. The compositions described herein are pharmaceutical or nutritional compositions suitable for preserving muscle mass, strength, and/or function in a subject in need thereof. The compositions are based on a specially formulated mixture of essential amino acids (EAAs) and protein with additional components. Use of the compositions herein may prevent muscle atrophy associated with periods of rest, such as those following surgery, injury, inactivity and during recovery from disease.